AdaptHealth Corp. $AHCO Shares Bought by Public Sector Pension Investment Board

Public Sector Pension Investment Board raised its stake in AdaptHealth Corp. (NASDAQ:AHCO) by 16.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 418,231 shares of the company’s stock after purchasing an additional 58,487 shares during the quarter. Public Sector Pension Investment Board owned 0.31% of AdaptHealth worth $3,743,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. AlphaQuest LLC lifted its holdings in shares of AdaptHealth by 275.7% during the second quarter. AlphaQuest LLC now owns 3,941 shares of the company’s stock worth $37,000 after purchasing an additional 2,892 shares during the period. Assetmark Inc. lifted its stake in shares of AdaptHealth by 87.6% in the 2nd quarter. Assetmark Inc. now owns 5,529 shares of the company’s stock worth $52,000 after acquiring an additional 2,581 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of AdaptHealth by 318.0% in the second quarter. Tower Research Capital LLC TRC now owns 9,592 shares of the company’s stock valued at $90,000 after acquiring an additional 7,297 shares in the last quarter. Tidal Investments LLC purchased a new stake in shares of AdaptHealth in the second quarter valued at about $96,000. Finally, CWM LLC increased its stake in shares of AdaptHealth by 1,562.1% during the second quarter. CWM LLC now owns 10,471 shares of the company’s stock worth $99,000 after acquiring an additional 9,841 shares during the period. Hedge funds and other institutional investors own 82.67% of the company’s stock.

AdaptHealth Stock Performance

NASDAQ AHCO opened at $10.34 on Friday. AdaptHealth Corp. has a 1-year low of $7.11 and a 1-year high of $11.63. The company has a market capitalization of $1.40 billion, a P/E ratio of 18.80, a PEG ratio of 1.14 and a beta of 1.72. The business has a 50 day moving average price of $10.27 and a 200 day moving average price of $9.66. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.08 and a quick ratio of 0.86.

Wall Street Analysts Forecast Growth

AHCO has been the subject of a number of recent analyst reports. Wall Street Zen downgraded shares of AdaptHealth from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Weiss Ratings raised AdaptHealth from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, January 30th. Zacks Research upgraded AdaptHealth from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Finally, Canaccord Genuity Group increased their price objective on AdaptHealth from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Four equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $14.25.

Insider Activity

In other news, Director David Solomon Williams III sold 5,000 shares of AdaptHealth stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $9.43, for a total transaction of $47,150.00. Following the completion of the transaction, the director owned 45,045 shares of the company’s stock, valued at $424,774.35. The trade was a 9.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 1.55% of the stock is owned by company insiders.

AdaptHealth Profile

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.